Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.

Competing Interests: YoK has received funds in the form of grants from the Center for Research on Influenza Pathogenesis and Transmission (75N93021C00014) by the National Institutes of Allergy and Infectious Diseases, and a research programme on emerging and re-emerging infectious diseases (JP21fk0108552 and JP21fk0108615), a project promoting support for drug discovery (JP21nf0101632), the Japan Program for Infectious Diseases Research and Infrastructure (JP22wm0125002), and the Japan Initiative for World-leading Vaccine Research and Development Centers (JP223fa627001) from the Japan Agency for Medical Research and Development. YoK has also received unrelated funding from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Shionogi, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seiyaku, Shinya, and Fuji Rebio. TK is employed by Nihon Sumo Kyokai. All other authors declare no competing interests. RU, MIt, and MKi contributed equally.